# 8 Weeks Versus 12 Weeks of Elbasvir/Grazoprevir in Treatment-naïve CHC With Mild Fibrosis

> **NCT03186365** · PHASE3 · COMPLETED · sponsor: **Kaohsiung Medical University Chung-Ho Memorial Hospital** · enrollment: 82 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** Zepatier Oral Product

## Key facts

- **NCT ID:** NCT03186365
- **Lead sponsor:** Kaohsiung Medical University Chung-Ho Memorial Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-12
- **Primary completion:** 2018-09-19
- **Final completion:** 2018-09-19
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2019-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03186365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03186365, "8 Weeks Versus 12 Weeks of Elbasvir/Grazoprevir in Treatment-naïve CHC With Mild Fibrosis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03186365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*